Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | BRD2 | P25440 | 1/20 | 0.38 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.38 |
| ▸ | ATR | Q13535 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.35 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | ACACA | Q13085 | 1/20 | 0.34 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.34 |
| ▸ | LCK | P06239 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30045766 | 1.00 | BRAF (0.41) | BRAFBRD4BRD2BRD3CREBBP | |
| SCHEMBL21783561 | 0.85 | BRAF (0.40) | BRAFBRD4BRD2BRD3CREBBP | |
| SCHEMBL21783559 | 0.84 | BRAF (0.39) | BRAFBRD4BRD2BRD3CREBBP | |
| SCHEMBL30045577 | 0.84 | BRAF (0.39) | BRAFBRD4BRD2BRD3CREBBP | |
| SCHEMBL16069701 | 0.83 | CYP17A1 (0.43) | BRAFCYP17A1ATRAAK1P2RX3 | |
| SCHEMBL31018064 | 0.83 | CYP17A1 (0.43) | BRAFCYP17A1ATRAAK1P2RX3 | |
| SCHEMBL23148155 | 0.81 | CYP17A1 (0.41) | BRAFCYP17A1ATRAAK1P2RX3 | |
| SCHEMBL21777273 | 0.80 | KEAP1 (0.41) | — | |
| SCHEMBL25027545 | 0.80 | BRD4 (0.40) | BRD4BRD2BRD3CREBBPDGAT1 | |
| SCHEMBL29361617 | 0.80 | BRD4 (0.40) | BRD4BRD2BRD3CREBBPDGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112638879-B | Heteroaryl substituted sulfonamide compounds and their use as therapeutic agents | 泽农医药公司 | 2024-06-18 | — | — | CN | disclosed |
| US-11639351-B2 | Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. | 2023-05-02 | — | — | US | disclosed |
| US-11639351-B2 | Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. | 2023-05-02 | — | — | US | disclosed |
| US-10981905-B2 | Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2021-04-20 | — | — | US | disclosed |
| US-20200157089-A1 | HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2020-05-21 | — | — | US | disclosed |
| WO-2020047323-A1 | HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2020-03-05 | — | — | WO | disclosed |
| US-20160220564-A1 | SUBSTITUTUED QUINOXALINES AS FGFR KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2016-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11639351-B2 | Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents | SCN1A, SCN2A, SCN2B | BRAF 414/4885BRD4 893/4885BRD2 1348/4885 |
| US-20200157089-A1 | HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | SCN1A, SCN2A, SCN2B | BRAF 414/4885BRD4 893/4885BRD2 1348/4885 |
| US-20160220564-A1 | SUBSTITUTUED QUINOXALINES AS FGFR KINASE INHIBITORS | FGFR1, FGFR3, FGFR4 | BRAF 24/4885BRD4 142/4885BRD2 864/4885 |
| US-10981905-B2 | Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents | SCN1A, SCN2A, SCN2B | BRAF 414/4885BRD4 893/4885BRD2 1348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.